• Medical Oncology
    • Chair, Department of Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research Medical Director, Clinical Trials Office Levine Cancer Institute at Atrium Health

    Edward S. Kim, MD is Chair of Solid Tumor Oncology and Investigational Therapeutics, Medical Director of the Clinical Trials Office, and the Donald S. Kim Distinguished Chair for Cancer Research at the Levine Cancer Institute, Atrium Health in Charlotte, NC. 

    Dr. Kim was previously at UT MD Anderson Cancer Center in Houston, Texas where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology. 

    Dr Kim received his Bachelor of Science and medical degrees from the Honors Program in Medical Education (HPME) at Northwestern University, his residency at Baylor College of Medicine, and his fellowship in medical oncology at UT MD Anderson Cancer Center. 

    Dr Kim specializes in cancer biomarkers and novel targeted agents in the treatment and prevention settings and has expertise in lung, head and neck cancers. He chaired the Department of Defense Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer. He currently oversees the solid tumor faculty and research development at Levine Cancer Institute. 

    Dr Kim is the author or coauthor of more than 100 published articles, book chapters, reviews in journals such as Lancet, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research Cancer, and Cancer Prevention Research, involving cancer therapeutics and prevention with chemotherapy and novel targeted agents, with particular emphases on lung cancer and head and neck cancer.

    • Hematology and Oncology
    Director, Genitoury Medical Oncology Program; Assistant Professor, Department of Medicine
    Director, Genitoury Medical Oncology Program; Assistant Professor, Department of Medicine
    • Associate Professor, Department of Medicine Director, Genitourinary Medical Oncology Program at Perlmutter Cancer Center at NYU Langone Health

    Arjun Balar, MD, is an Assistant Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health.

    He received his medical degree from the University of South Florida – College of Medicine as a member of the Alpha-Omega-Alpha Honor Medical Society.  Dr. Balar completed his internal medicine residency at New York-Presbyterian Hospital – Weill Cornell Medical Center and went on to complete a fellowship in medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center where he focused his research efforts entirely on novel therapies in muscle-invasive and metastatic bladder cancer. Dr. Balar has focused primarily on cisplatin-ineligible patients with the goal of identifying better-tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer, with a particular focus on novel immunotherapies and combinations.

  • Co-Leader, Gastrointesinal Cancer Program
    Co-Leader, Gastrointesinal Cancer Program
    • Professor, Mayo Clinic College of Medicine and Science Program Leader, Gastrointestinal Cancer at Mayo Clinic College of Medicine

    Tanios Bekaii-Saab, MD, is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA. He is also the consortium chair for the ACCRU research Network.

    Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.

    Dr. Bekaii-Saab, MD, conducts clinical and translational research focused on developing anticancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. Bekaii-Saab’s research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. His work includes 2 recent discoveries as coinventor of a molecule that targets cancer-related cachexia (AR-42) and an anti–PD-1 vaccine. His research has also led to the launch of a number of phase II and III clinical trials, including a recent trial with a cancer stem cell inhibitor (napabucasin) in pancreatic cancer, the development of an FGFR inhibitor in bile duct cancers, and a contribution to the pivotal study that led to the regulatory approval of nanoliposomal irinotecan for treating pancreatic cancer.

    Dr. Bekaii-Saab has authored or co-authored more than 350 peer reviewed publications, abstracts, and book chapters, including papers in such journals as Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research. 

  • Chief, Translational Research and Immunotherapy; Director, Phase I Immuno-oncology program
    Chief, Translational Research and Immunotherapy; Director, Phase I Immuno-oncology program

    Omid Hamid, MD, is chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute. He also serves as the director of the Melanoma and Phase I programs. His areas of expertise include immunotherapy and phase I drug development. Dr. Hamid has published extensively and has been at the forefront of the development of paradigm-shifting breakthroughs, including BRAF/MEK targeted agents and anti-CTLA4, anti–PD-1, and PD-L1 therapies. His current interests include new immunotherapeutic options, including bispecific antibodies, adoptive T-cell therapy, and oncolytic therapies with a focus on combinatorial approaches resulting in potentially greater patient benefit. Through his leadership, The Angeles Clinic has fostered a program that combines expert clinical care with teaching and leading clinical research.

    • Hematology and Oncology
    • Ingram Associate Professor of Cancer Research, Assistant Vice Chairman for Faculty Development, Director Thoracic Oncology Program at Vanderbilt Ingram Cancer Center

    Leora Horn, MD, MSc, is an Associate Professor of Medicine and Director of the Thoracic Oncology Program at Vanderbilt Ingram Cancer Center (VICC) in Nashville, Tennessee. She is also the Assistant Vice Chairman for Faculty Development at Vanderbilt University Medical Center. Her clinical practice focuses on the care of patients with lung cancer. She is an active member of the Eastern Cooperative Oncology Group, the International Association for the Study of Lung Cancer, and the American Society of Clinical Oncology. She has over 120 publications, including in the New England Journal of Medicine, Nature Medicine, and Journal of Clinical Oncology. In the last 8 years, she has been among the top 5 in accrual to clinical trials at VICC, where she has a focus on clinical trials with targeted therapies and immunotherapy, as well as small cell lung cancer. Dr. Horn works closely with many collaborators at VICC, where she translates laboratory findings into clinical trials for patients with lung cancer.

    • Professor of Medicine Chief, Myeloma Service Department of Medicine at Memorial Sloan Kettering Cancer Center

    Ola Landgren, MD, PhD, earned his medical degree in 1995 from Karolinska Institute, Stockholm, Sweden. Currently, Dr. Landgren is Professor of Medicine and chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York. He holds a PhD in diagnostics and prognostics in lymphoid malignancies from Karolinska Institute. He has published over 300 papers, including a definitive prospective cancer screening study showing that myeloma is consistently preceded by a precursor state. Since 2007, Landgren’s translational research has particularly focused on the development of early treatment strategies in newly diagnosed multiple myeloma patients and high risk smoldering myeloma patients, paired with novel minimal residual disease (MRD) assays. For years, he has been involved in the development of many novel drugs for multiple myeloma. He is a frequently invited speaker at national and international meetings and he serves on several editorial boards

    • Hematology and Oncology
    • Associate Professor of Medicine, Director of Community Outreach at University of Miami Miller School of Medicine

    Reshma Mahtani, DO, is a board-certified hematologist and medical oncologist with a practice focused on breast cancer. She is an associate professor of clinical medicine in the Division of Hematology/Oncology at the Sylvester Cancer Center, University of Miami. Dr. Mahtani has served as institutional principal investigator on several phase II and III breast cancer clinical trials. Dr. Mahtani has spoken nationally and internationally on various aspects of breast cancer care. She is an editorial board member for The Breast Journal and the educational website Practice Updates. She has served as medical director for several officially licensed Best of American Society of Clinical Oncology (ASCO) programs and is a member of the ASCO Quality Oncology Practice Initiative Steering Committee.

Powered by Medstro